Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 허준영 | - |
dc.date.accessioned | 2022-09-28T05:18:45Z | - |
dc.date.available | 2022-09-28T05:18:45Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.citation | IMMUNE NETWORK, v. 20, no. 6, article no. e48, page. 1-11 | en_US |
dc.identifier.issn | 1598-2629; 2092-6685 | en_US |
dc.identifier.uri | https://immunenetwork.org/DOIx.php?id=10.4110/in.2020.20.e48 | en_US |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/174995 | - |
dc.description.abstract | Hyperprogressive disease (HPD) is a distinct pattern of progression characterized by acceleration of tumor growth after treatment with anti-PD-1/PD-L1 Abs. However, the immunological characteristics have not been fully elucidated in patients with HPD. We prospectively recruited patients with metastatic non-small cell lung cancer treated with anti-PD-1/PD-L1 Abs between April 2015 and April 2018, and collected peripheral blood before treatment and 7-days post-treatment. HPD was defined as ˃= 2-fold increase in both tumor growth kinetics and tumor growth rate between pre-treatment and post-treatment. Peripheral blood mononuclear cells were analyzed by multi-color flow cytometry to phenotype the immune cells. Of 115 patients, 19 (16.5%) developed HPD, 52 experienced durable clinical benefit (DCB; partial response or stable disease ˃= 6 months), and 44 experienced non-hyperprogressive progression (NHPD). Patients with HPD had significantly lower progression-free survival (p˂0.001) and overall survival (p˂0.001). When peripheral blood immune cells were examined, the pre-treatment frequency of CD39(+) cells among CD8(+) T cells was significantly higher in patients with HPD compared to those with NHPD, although it showed borderline significance to predict HPD. Other parameters regarding regulatory T cells or myeloid derived suppressor cells did not significantly differ among patient groups. Our findings suggest high pre-treatment frequency of CD39(+)CD8(+) T cells might be a characteristic of HPD. Further investigations in a larger cohort are needed to confirm our results and better delineate the immune landscape of HPD. | en_US |
dc.description.sponsorship | This study was supported by the National Research Foundation (grant NRF-2018M3A9D3079498), which is funded by the Ministry of Science and ICT. | en_US |
dc.language.iso | en | en_US |
dc.publisher | KOREA ASSOC IMMUNOLOGISTS | en_US |
dc.subject | Hyperprogressive disease; PD-1-PD-L1 blockade; Lung cancer; Peripheral blood human mononuclear cells; CD39; T cell | en_US |
dc.title | Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs | en_US |
dc.type | Article | en_US |
dc.relation.no | 6 | - |
dc.relation.volume | 20 | - |
dc.identifier.doi | 10.4110/in.2020.20.e48 | en_US |
dc.relation.page | 1-11 | - |
dc.relation.journal | IMMUNE NETWORK | - |
dc.contributor.googleauthor | Kim, Kyung Hwan | - |
dc.contributor.googleauthor | Hur, Joon Young | - |
dc.contributor.googleauthor | Koh, Jiae | - |
dc.contributor.googleauthor | Cho, Jinhyun | - |
dc.contributor.googleauthor | Ku, Bo Mi | - |
dc.contributor.googleauthor | Koh, June Young | - |
dc.contributor.googleauthor | Sun, Jong-Mu | - |
dc.contributor.googleauthor | Lee, Se-Hoon | - |
dc.contributor.googleauthor | Ahn, Jin Seok | - |
dc.contributor.googleauthor | Park, Keunchil | - |
dc.relation.code | 2020053741 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | deliverus | - |
dc.identifier.orcid | https://orcid.org/0000-0003-0092-8370 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.